MedTrace Logo

Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma

NCT02825147 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-11-14

No results posted yet for this study

Summary

Extranodal NK/T cell lymphoma is an aggressive tumor with higher incidence in Asia.Traditional CHOP/CHOP-like regiment can't produce satisfied outcome for the patients. Asparaginase-based treatment has been demonstrated as promising response rate and survival superiority. Stage-specified regimen may bring out exciting efficacy with good safety.

Conditions

  • Nasal Type Extranodal NK/T-Cell Lymphoma

Interventions

DRUG

Pegaspargase

DRUG

Methotrexate

DRUG

Dexamethasone

DRUG

Etoposide

RADIATION

radiotherapy

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • ZHAO WEILI, PhD,MD · Ruijin Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-03-31
Completion
2017-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02825147 on ClinicalTrials.gov